Abstracts tagged "Lupus nephritis"

Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Samantha Chalmers¹, Sayra Garcia ¹, Rajalakshmy Ayilam Ramachandran ², Chandra Mohan ², Jeanette Ampudia ³, Cherie Ng ³, Stephen Connelly ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, ³Equillium, Inc, San Diego, CA, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…
Abstract Number: 1128 • 2019 ACR/ARP Annual Meeting
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Sofia Georgopoulou¹, Louise Nel ², Shirish Sangle ² and David D'Cruz ³, ¹King's College London & The Royal Marsden Hospital NHS Foundation Trust, London, England, United Kingdom, ²Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis…
Abstract Number: 2542 • 2019 ACR/ARP Annual Meeting
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Minlin Zhou¹, Yang yang ², Xiaoyan Han ², Xin Yu ² and Haitao zhang ¹, ¹National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China (People's Republic), ²Shanghai Roche Pharmaceuticals Ltd, Shanghai, China (People's Republic)
Background/Purpose: Achieving clinical remission while reducing toxicity are primary objectives in the treatment of lupus nephritis (LN). Mycophenolate mofetil (MMF) has demonstrated efficacy benefits with…
Abstract Number: 735 • 2018 ACR/ARHP Annual Meeting
Serum Albumin at One Year Predicts Long-Term Renal Outcome
Vinicius Domingues¹, Daniel Goldman², Laurence S Magder³ and Michelle Petri², ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis remains a major cause of morbidity/mortality in SLE. Our cohort has shown that 20% of SLE patients with lupus nephritis onset…
Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting
Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
Yair Molad^1,2, Mohammad Egbaria³, Ariela Dortort-Lazar^4,5, Elisheva Pokroy-Shapira^3,5, Shirly Oren⁴, Yonatan Edel^3,5 and Vitaly Kliminski^5,6, ¹Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, ²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁴Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
Abstract Number: 749 • 2018 ACR/ARHP Annual Meeting
Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Joan T. Merrill¹ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁴Nephrology Division, UT Southwestern Medical Center, Dallas, TX, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus Nephritis (LN) usually presents within 5 years of SLE diagnosis, however the minority of patients with late-occurring nephritis are poorly characterized. Factors associated…
Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Kubra Bugdayli¹, Cynthia S. Crowson², Ladan Zand³, Mariam P. Alexander⁴, Lynn D. Cornell⁴ and Vaidehi R. Chowdhary⁵, ¹Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ⁴Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Pei Han¹, Christopher Pohlmeyer¹, Ching Shang¹, Zhihua Cui², David Lopez³, Astrid Clarke², Randall Jones², Nevena Mollova³, Igor Mikaelian⁴, David Newstrom³, Shiva Zaboli³, Allyson Shauf³ and Julie Di Paolo⁵, ¹Immunology and Inflammation, Gilead Sciences, Foster City, CA, ²Gilead Sciences, Seattle, WA, ³Gilead Sciences, Foster City, CA, ⁴Biology Core Support, Gilead Sciences, Foster City, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…
Abstract Number: 2110 • 2018 ACR/ARHP Annual Meeting
Association of Systemic Lupus Erythematosus (SLE) Genetic Susceptibility Loci with Lupus Nephritis in Children and Adults with SLE
Declan Webber¹, Jingjing Cao², Daniela Dominguez³, Dafna D Gladman⁴, Deborah M. Levy⁵, Lawrence Ng³, Andrew Paterson³, Zahi Touma⁶, Murray Urowitz⁷, Joan E. Wither⁸, Earl Silverman⁵ and Linda Hiraki⁹, ¹Department of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disease. Genome-wide association studies (GWAS) have identified multiple risk SNPs in HLA and non-HLA gene…
Abstract Number: 2153 • 2018 ACR/ARHP Annual Meeting
The Effect of Socioeconomic Status on Treatment Outcomes in Lupus Nephritis: Private Versus Public Insurance
Arezoo Haghshenas¹, Phildrich Teh², Kristal Choi³, Abigail Benitez⁴, Lorena Salto³, Mathew Firek⁵, Karina Torralba⁶ and Vaneet K. Sandhu¹, ¹Division of Rheumatology, Loma Linda University, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University, Loma Linda, CA, ⁵Riverside university health system, Moreno valley, CA, ⁶Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Despite therapeutic advancements, lupus nephritis (LN) remains a major cause of mortality among patients with SLE. Loma Linda University Health serves a region in…
Abstract Number: 2416 • 2018 ACR/ARHP Annual Meeting
Good Pregnancy and Neonatal Outcomes in Lupus Nephritis Patients with Complete Remission
Weixin HU, Kang LI, Yinghua CHEN, Zhenzhao LIU, Liu YANG, Duqun CHEN and Haitao Zhang, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
Background/Purpose: To investigate the outcomes of pregnancy and neonatal and the risk factors of lupus flares and pregnancy complications in Chinese patients with lupus nephritis…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 2636 • 2018 ACR/ARHP Annual Meeting
Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database
Osman Bhatty¹, Sarah Aurit², Rouhin Sen³, Joseph Nahas⁴ and Sunil Jagadesh⁵, ¹Department of Medicine, CHI Creighton University Medical Center, New Hempstead, NY, ²Department of Surgery, CHI Creighton University Medical Center, Omaha, NE, ³Internal Medicine, CHI Creighton University Medical Center, Omaha, NE, ⁴Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE, ⁵Department of Nephrology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Twenty to sixty percent of patients with systemic lupus erythematous (SLE) can progress to lupus nephritis (LN) and those that do can develop end…
Abstract Number: 2662 • 2018 ACR/ARHP Annual Meeting
Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
L. Michelle Gomez Mendez¹, Marco Prunotto², Jian Dai³, Paul Brakeman¹, Maria Dall'Era¹, Jay Garg³ and Matthew Cascino³, ¹UCSF, San Francisco, CA, ²Hoffmann-La Roche, Basel, Switzerland, ³Genentech, Inc., South San Francisco, CA
Background/Purpose: Hypertension predicts poor long-term renal outcomes for patients with lupus nephritis (LN) [1, 2]. We sought to characterize relationships between blood pressure and proteinuria…
Abstract Number: PP11 • 2018 ACR/ARHP Annual Meeting
The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes
Carlene Harrison, AstraZeneca, Gaithersburg, MD
Background/Diagnosis: African-American female diagnosed with SLE, Lupus Nephritis, Discoid Lupus, and Raynaud’s Phenomenon in 2011. Symptoms included joint pain, edema in the ankles, malar rash,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].